## PD-1-IN-24

Cat. No.:HY-134886CAS No.:2360909-50-6Molecular Formula: $C_{27}H_{26}F_3NO_3$ Molecular Weight:469.5Target:PD-1/PD-L1Pathway:Immunology/InflammationStorage:-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	F F H OH OH
--	-------------------------

## SOLVENT & SOLUBILITY

	Preparing Stock Solutions	Mass Solvent Concentration	1 mg	5 mg	10 mg	
		1 mM	2.1299 mL	10.6496 mL	21.2993 mL	
		5 mM	0.4260 mL	2.1299 mL	4.2599 mL	
		10 mM	0.2130 mL	1.0650 mL	2.1299 mL	
	Please refer to the sc	lubility information to select the ap	propriate solvent.			
In Vivo		one by one: 10% DMSO >> 40% PE( nL (10.65 mM); Suspended solution;		0 >> 45% saline		
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5 mg/mL (10.65 mM); Clear solution					
		one by one: 10% DMSO >> 90% cor /mL (10.65 mM); Clear solution	n oil			

BIOLOGICAL ACTIVITY				
Description	PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor <sup>[1]</sup> .			
In Vivo	PD-1-IN-24 (compound 1, 15mg/kg, PO, BID) exhibits TGI(%) of 19.96% in the subcutaneous 4T1 murine breast cancer model in BALB/c mice <sup>[1]</sup> . PD-1-IN-24 (compound 1, 15mg/kg, PO, BID) dose-dependently inhibits tumor growth in the Bl6F10 models with TGI% of 35.59% (30 mg/kg), 38.87% (60 mg/kg) and 47.35% (120 mg/kg), respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			



## REFERENCES

[1]. Wang, Yuguang, et al. Combination of small molecule inhibitor of the PD-1/PD-L1 interaction and anti-PD-1 antibody for treatment of cancer. Patent WO 2021052386.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA